Document is current

Article History

Received: 6 August 2024

Accepted: 10 October 2024

First Online: 25 November 2024

Declarations

:

: Gabrielle Rocque: receives research funding from Genentech, Pfizer, Daiichi Sankyo; paid consultant: Pfizer, Gilead, and Armada. Joanne L. Blum: paid consultant: Pfizer, Inc., Tempus, TD2; Speaker's Bureau: Pfizer, Tempus. Yan Ji: received compensation for advisory board: AstraZeneca, BMS. Timothy Pluard: paid consultant: Pfizer, AstraZeneca, Jazz Pharmaceutical, Daiichi, Gilead; research funding (institution): Daiichi Sankyo, Jazz Pharmaceuticals, Pfizer, Sermonix, Scorpion, Merck, DualityBio, Arvinas; Speaker’s Bureau: Gilead, AstraZeneca, Stemline. John Migas: contracted research (clinical trials) paid to institution (Pfizer, Inc., AstraZeneca, Jazz Pharmaceuticals. Shailendra Lakhanpal: reports no conflicts of interest. Erin Jepsen: employed by Novant Health Cancer Institute. Eric Gauthier: Pfizer employee and owns PFE stock. Yao Wang: Pfizer employee and owns PFE stock. Monica Z. Montelongo: employee of ICON, which was a paid consultant to Pfizer in connection with the development of this manuscript. Joseph C. Cappelleri: Pfizer employee and owns PFE stock Meghan S. Karuturi: reports no conflicts of interest. Debu Tripathy: contracted research (clinical trials) paid to institution: Novartis, Pfizer, Polyphor; paid consultant: AstraZeneca, OncoPep, GlaxoSmithKline, Gilead, Personalis, Sermonix, Pfizer, AMBRX, Novartis, Puma Biotechnology, Roche, Menarini, BeiGene, Jazz Pharmaceuticals.

: The study protocol, protocol amendments, final approved informed consent and assent documents, and all relevant supporting information were submitted by the investigator to the institutional review board (IRB) and approved by the IRB and regulatory agency (as appropriate) before study initiation.